Next 10 |
home / stock / iphyf / iphyf news
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below. Participants will include Hervé...
Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate’s second generation ANKET ® , for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma ...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 23, 2024, in Marseille. All r...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanof...
Two abstracts on SAR443579 (IPH6101), ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate’s second generation ANKET ® for the treatment of relap...
2024-05-14 11:03:08 ET Innate Pharma S.A. (IPHA) Q1 2024 Results Conference Call May 14, 2024 08:00 AM ET Company Participants Henry Wheeler - Head, Investor Relations Herve Brailly - Interim Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yan...
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...